Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: A randomized, dose-escalation, placebo-controlled study

Journal of Dermatological Science

Volumn 75, Issue 3, 2014, Pages 201-204

  Osamu, Nemoto ^a   Hirotaka, Nagashima ^b   Koji, Sayama ^c   Kenji, Takazawa ^d  

^a Sapporo Skin Clinic   (Japan)

^b Yanagibashi Hospital   (Japan)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Medical Corporation Shinanokai   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRODALUMAB; INTERLEUKIN 17; INTERLEUKIN 17RA; KHK 4827; PLACEBO; UNCLASSIFIED DRUG; CYTOKINE; INTERLEUKIN 17 RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION SITE ERYTHEMA; JAPANESE (PEOPLE); LETTER; MALE; PHASE 1 CLINICAL TRIAL; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; SYSTEMIC THERAPY; CHEMISTRY; DOSE RESPONSE; IMMUNOLOGY; JAPAN; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PSORIASIS; QUALITY OF LIFE; TIME; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTHY VOLUNTEERS; HUMANS; JAPAN; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; RECEPTORS, INTERLEUKIN-17; TIME FACTORS; YOUNG ADULT;

EID: 84904983689     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.05.007     Document Type: Letter

References (9)

1. Ghoreschi K., Weigert C., Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007, 25:574-580.
2. Stern R.S., Nijsten T., Feldman S.R., Margolis D.J., Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004, 9:136-139.
3. Kurd S.K., Gelfand J.M. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009, 60:218-224.
4. Chandran V., Raychaudhuri S.P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010, 34:J314-J321.
5. Kawada A., Tezuka T., Nakamizo Y., Kimura H., Nakagawa H., Ohkido M., et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci 2003, 31:59-64.
6. Martin D.A., Towne J.E., Kricorian G., Klekotka P., Gudjonsson J.E., Krueger J.G., et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2013, 133:17-26.
7. Chang S.H., Reynolds J.M., Pappu B.P., Chen G., Martinez G.J., Dong C. Interleukin-17C promotes Th17cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 2011, 35:611-621.
8. Papp K.A., Reid C., Foley P., Sinclair R., Salinger D.H., Williams G., et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012, 132:2466-2469.
9. Papp K.A., Leonardi C., Menter A., Ortonne J.P., Krueger J.G., Kricorian G., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366:1181-1189.